Lonza announced Swissmedic approval and GMP licensing for a new aseptic drug‑product filling line in Stein, Switzerland, configured for highly potent biologics including ADCs and other modalities requiring advanced containment. The facility adds liquid and lyophilized vial filling capacity with next‑generation containment/isolation systems and aligns with Lonza’s integrated biologics strategy connecting substance and product capabilities. Lonza framed the line as enabling clinical and commercial supply for customers developing potent modalities and as complementary to existing Basel capabilities. For readers: regulatory‑approved high‑potency filling lines are critical bottleneck relief for ADC and bispecific developers who face containment and capacity constraints in scale‑up.